First Majestic Silver Q3 production falls 11% to 3.4 million oz amid San Dimas labor dispute
Bitget2026/10/08 11:05First Majestic posted Q3 2026 output of 3,440,447 silver oz, down 11% year over year, citing a 12-day San Dimas labor disruption. Gold production fell 17% to 29,552 oz; zinc slipped 4% to 13,277,264 lb; lead rose 2% to 7,839,182 lb. Copper production declined 8% to 221,111 lb; ore processed increased 9% to 1,088,708 tonnes. San Dimas output dropped 41% to 859,869 silver oz; gold fell 26% to 10,386 oz, reflecting lower grades. TSX accepted a renewed buyback starting Oct. 14, capped at 10,000,000 shares, about 2% of 493,080,912 outstanding. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. First Majestic Silver Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202610080700NEWSFILECNPR____20261008_318032_1) on October 08, 2026, and is solely responsible for the information contained therein.
- First Majestic posted Q3 2026 output of 3,440,447 silver oz, down 11% year over year, citing a 12-day San Dimas labor disruption.
- Gold production fell 17% to 29,552 oz; zinc slipped 4% to 13,277,264 lb; lead rose 2% to 7,839,182 lb.
- Copper production declined 8% to 221,111 lb; ore processed increased 9% to 1,088,708 tonnes.
- San Dimas output dropped 41% to 859,869 silver oz; gold fell 26% to 10,386 oz, reflecting lower grades.
- TSX accepted a renewed buyback starting Oct. 14, capped at 10,000,000 shares, about 2% of 493,080,912 outstanding.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
WTI Price Forecast: Slides further below $100.50; bullish potential seems intact
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.
Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks
Goldman Sachs stated that the Japanese yen has become a better tool for hedging against AI shocks, with policy shifts reducing the risk of depreciation. The bank recommends shorting USD/JPY and EUR/JPY.
